Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights EXTON, PA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this...

Neuronetrix publishes peer-reviewed paper validating the clinical application of ERP biomarkers for use in Alzheimer's disease LOUISVILLE, Ky., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Neuronetrix announced today the publication of results from its multi-center clinical trial in a prestigious Alzheimer's journal. The report, "A...

Neuronetrix joins big pharma to sponsor conference on Clinical Trials for Alzheimer's Disease LOUISVILLE, Ky., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Neuronetrix announced today that it has joined pharma giants Lilly, Roche, Lundbeck, Janssen, and others to sponsor the 8th Annual Clinical Trials on...